Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia

This study has been completed.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Information provided by (Responsible Party):
M.D. Anderson Cancer Center Identifier:
First received: June 19, 2002
Last updated: July 31, 2012
Last verified: July 2012
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: March 2009
  Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)